Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer
22.10.2026 12:18:00 CEST | Business Wire | Press Release
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden.
Independent, Blinded Evaluation Using Phase III Trial Data
The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified protocol and statistical analysis plan.
Within this clinically high-risk population, myStage Dx identified two groups with markedly different long-term outcomes. The Low Risk group comprised 23.5% of patients. At ten years, the estimated proportion alive and free from breast cancer recurrence was 96.1% in the Low Risk group, compared with 76.6% in the Not Low Risk group. The difference remained statistically significant after adjustment for standard clinicopathological prognostic factors. These findings build on earlier evidence from the CANTO and UNIRAD trial cohorts, published in the Journal of Clinical Oncology in 2025.
“Confidence in a clinical test has to be earned through independent scrutiny. We chose a blinded evaluation of myStage Dx by an independent research team, accepting that the results were outside our control. These findings are consistent with our previous studies and reinforce the test’s ability to address a concrete clinical problem: identifying patients with a favorable prognosis despite clinically high-risk disease, with a clear risk classification to inform treatment discussions,” says Dr. Marvin Lerousseau, co-founder and CSO of Spotlight Medical.
Refining Recurrence Risk Assessment to Support Clinical Decision-Making
Patients considered clinically high-risk may be eligible for additional treatment, including CDK4/6 inhibitors, yet their individual recurrence risks can vary substantially. In PANTHER, patients received chemotherapy and endocrine therapy without CDK4/6 inhibitors. By identifying a subgroup with favorable long-term outcomes under those treatment conditions, myStage Dx provides prognostic information to inform discussions about treatment strategy. These discussions should consider individual recurrence risk, the expected benefits and risks of additional treatment, and patient preferences, consistent with ASCO guidance.
“As ASCO guidelines highlight, accurately assessing recurrence risk is essential to treatment decisions. For patients, additional therapies can mean up to three more years of treatment, with side effects, anxiety, and a real impact on daily life. We are proud to show how myStage Dx can help oncologists better assess individual risk and support more informed clinical decisions, with the aim of improving patient care,” said Sylvain Berlemont, co-founder and CEO of Spotlight Medical.
About Spotlight Medical
Spotlight Medical is an oncology diagnostics company developing evidence-driven, clinical-grade AI tests to support more precise cancer care. The company combines routine pathology, clinical data and explainable AI to develop prognostic assays designed for practical adoption in oncology workflows.
About myStage Dx
myStage Dx is a software-only in vitro diagnostic medical device that has received CE marking under the European Union IVDR. It combines the analysis of a digitized histopathology slide with routinely available clinicopathological data to generate a prognostic classification intended for use by qualified healthcare professionals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261022574100/en/
Contacts
Media
press@spotlightmedical.com
spotlightmedical.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fspotlightmedic
al.com%2F&esheet=54627090&newsitemid=20261022574100&lan=en-US&anchor=spotlightme
dical.com&index=1&md5=f6a93b8817f529c2274e100c48dbb04f | mystagedx.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmystagedx.com%
2F&esheet=54627090&newsitemid=20261022574100&lan=en-US&anchor=mystagedx.com&inde
x=2&md5=fc7f0cfa16f303900779b6b6ec4bd195
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology9.11.2026 12:45:00 CET | Press Release
Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT), today announced a global strategic collaboration with Biochar Now to expand the distribution of verified, insured carbon removal credits through Datavault’s patented tokenization technology and global marketing and distribution capabilities. The partnership is designed to connect Biochar Now’s carbon removal credits with a broader network of buyers while strengthening transparency, traceability and accountability in the carbon markets. Under the agreement, Datavault AI will provide access to its carbon credit tokenization technology, including U.S. Patent No. 12,443,977 and related pending applications. It will also support worldwide demand generation, buyer development, marketing and distribution of eligible Biochar Now carbon credits, while also pursuing listings with existing and future partner exchange platforms. Biochar Now will pay Datavault AI for its technology and services; specific financial terms were not discl
NIQ to Present at 2026 J.P. Morgan Ultimate Services Investor Conference9.11.2026 12:45:00 CET | Press Release
NielsenIQ (NYSE: NIQ) (the “Company”, or “NIQ”), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, and Mike Burwell, CFO will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026 at 2:40 pm ET. A live webcast will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior. Combining an unmatched global data footprint, granular consumer and retail measurement, and decades of AI modeling expertise, NIQ helps companies turn complex data into confident action. With operations in more than 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in consumer spend, N
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 12:30:00 CET | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The completion of our NDA submission reflects years of perseverance and commitment by patients, families, advocates, researchers and healthcare providers who have worked alongside us toward the shared goal of bringing new treatment options to this community,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “Compass is leading the development of this new class of medicines with rigor and discipline, successfully
Semiconductor Companies Get Tough on AI Investment, but Measuring Returns Remains a Challenge9.11.2026 12:03:00 CET | Press Release
HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109039341/en/ HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. Nearly half (48%) of semiconductor respondents describe their organizations as scaling AI or already AI-native, compared with 44% across the overall sample. Yet AI investment growth is broadly in line with the wider market, with 78% reporting increased investment over the past year
GoFundMe Surpasses $50 Billion Raised, Celebrating the People Powering a Global Movement of Help9.11.2026 12:00:00 CET | Press Release
GoFundMe today announced that its global community has surpassed $50 billion raised to help individuals and nonprofits around the world. More than 200 million people have donated through GoFundMe, and nearly 40% have given more than once, reflecting the extraordinary scale of people showing up for one another – and continuing to come back to help. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109255455/en/ Celebrating $50B raised on GoFundMe with The Kind 50. From showing up for a friend in need to mobilizing entire communities, The Kind 50 celebrates people and organizations whose acts of kindness – on and off GoFundMe – made an impact over the past year and inspired others to help. To mark the milestone, GoFundMe is introducing The Kind 50, a celebration of the internet’s kindest people. The inaugural list features 50 stories of individuals and nonprofits who saw a need, showed up, and brought others together to help.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom